Remimazolam Tosilate + Propofol
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Sedation
Conditions
Sedation
Trial Timeline
Nov 1, 2016 → Mar 1, 2017
NCT ID
NCT03003884About Remimazolam Tosilate + Propofol
Remimazolam Tosilate + Propofol is a phase 2 stage product being developed by Jiangsu Hengrui Medicine for Sedation. The current trial status is completed. This product is registered under clinical trial identifier NCT03003884. Target conditions include Sedation.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (6)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04400201 | Phase 3 | Completed |
| NCT03921775 | Phase 3 | Completed |
| NCT03779061 | Phase 3 | Completed |
| NCT03425474 | Phase 3 | Completed |
| NCT03003884 | Phase 2 | Completed |
| NCT02406872 | Phase 2 | Completed |
Competing Products
20 competing products in Sedation